MDMA
Understanding Optimi’s MDMA Offering
End-To-End Production
As an end-to-end supplier of psychedelic medicines, Optimi Health manufactures OPTI-MHCL, our novel MDMA formulation, entirely in-house and under the strictest possible standards of quality assurance. Our uniquely efficient, stable production process allows us to scale our output according to demand without complicating our supply chain logistics or compromising on purity.
OPTI-MHCL was tested for purity on-site with a result of >99%.
Patient Access In A Changing World
With the impact of post-traumatic disorders being felt more keenly than ever as part of a worldwide mental health crisis, the continued success of clinical trials, and the reclassification of psychedelic treatments across new jurisdictions, calls for legal access to therapeutic MDMA have never been louder.
OPTI-MHCL is here to make a meaningful impact on the lives of patients in need.
The Optimi Advantage
Optimi is currently the only publicly listed psychedelics company licensed by Health Canada to possess, produce, assemble, sell, and supply its formulation in patient-ready encapsulated doses across global markets.
OPTI-MHCL drug candidates are being offered in 40mg, 60mg, and 120mg dosage formats and can be formulated to meet the industry-leading MAPS Phase 3 trial protocol.
Training Therapists
In collaboration with ATMA Journey Centers, Optimi has initiated a Phase I combinatorial study that will document the safety of OPTI-MHCL, along with our natural psilocybin standardized extract and drug candidate in healthy therapist subjects.
Therapists who are provided with experiential training using both substances will in turn be able to provide greater value and higher standards of care to patients undergoing these treatments.
The Australian Market
On February 3, 2023, the Australian Government’s Department of Health and Aged Care published its “Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists”, which expands the Authorized Prescriber Scheme under Australia’s Therapeutic Goods Administration to offer MDMA and psilocybin as of July 1, 2023.
On February 3, 2023, the Australian Government’s Department of Health and Aged Care published its “Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists”, which expands the Authorized Prescriber Scheme under Australia’s Therapeutic Goods Administration to offer MDMA and psilocybin as of July 1, 2023.
Optimi Health has been engaged on an ongoing basis by Mind Medicine Australia, the leading Australian charitable organization advocating for psychedelic therapies for mental health treatments, to supply OPTI-MHCL for sufferers of post-traumatic stress disorders.
Optimi Health has been engaged on an ongoing basis by Mind Medicine Australia, the leading Australian charitable organization advocating for psychedelic therapies for mental health treatments, to supply OPTI-MHCL for sufferers of post-traumatic stress disorders.
For Australian researchers or clinicians looking to access OPTI-MHCL by July 1, 2023, please contact us at sales@optimihealth.ca.
For details on our GMP facilities and the recent distribution agreement with Mind Medicine Australia, please visit our YouTube page.
